Neumora Therapeutics
Yahoo Finance • 10 days ago
Apple initiated, Hershey upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Arete upgraded Baidu (BIDU) to Buy fro... Full story
Yahoo Finance • 2 months ago
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215
Earnings Call Insights: Neumora Therapeutics (NMRA) Q2 2025 MANAGEMENT VIEW * Paul L. Berns, Chief Executive Officer, stated that Neumora "prioritized obesity as the lead indication for NMRA-215, our highly brain-penetrant NLRP3 inhibi... Full story
Yahoo Finance • 2 months ago
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-st... Full story
Yahoo Finance • 2 months ago
Neumora Therapeutics soars 68% following InvestingPro's June Fair Value signal
InvestingPro’s Fair Value model recently demonstrated its effectiveness by identifying a significant opportunity in Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company. The model’s June 13 analysis flagged NMRA... Full story
Yahoo Finance • 3 months ago
H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock
Investing.com - H.C. Wainwright has reiterated its Buy rating and $18.00 price target on Neumora Therapeutics (NASDAQ:NMRA) following the company’s selection of a new lead M4 PAM candidate for schizophrenia treatment. According to Invest... Full story
Yahoo Finance • 3 months ago
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (... Full story
Yahoo Finance • 4 months ago
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareh... Full story
Yahoo Finance • 5 months ago
Galapagos Announces Executive Leadership Updates
Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans... Full story
Yahoo Finance • 5 months ago
Galapagos kondigt wijzigingen aan in uitvoerend leiderschap
De heer Henry Gosebruch benoemd door de Raad van Bestuur van Galapagos als oprichtend CEO van het nieuw opgerichte SpinCo Dr. Paul Stoffels, Voorzitter en CEO van Galapagos, is van plan in pensioen te gaan als CEO na benoeming van een opv... Full story
Yahoo Finance • 6 months ago
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (... Full story
Yahoo Finance • 6 months ago
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA... Full story
Yahoo Finance • 6 months ago
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRA
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: T... Full story
Yahoo Finance • 6 months ago
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
NEW YORK, April 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement... Full story
Yahoo Finance • 6 months ago
NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, Pa., April 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Souther... Full story
Yahoo Finance • 6 months ago
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Neumora To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Neum... Full story
Yahoo Finance • 6 months ago
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA)
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: T... Full story
Yahoo Finance • 6 months ago
NMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement... Full story
Yahoo Finance • 6 months ago
NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Souther... Full story
Yahoo Finance • 6 months ago
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Neumora pursuant and/or... Full story
Yahoo Finance • 6 months ago
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: T... Full story
